Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,131

The results emphasized the role of body posture and stomach motility in drug bioavailability.

* Researchers from Johns Hopkins University and Johns Hopkins School of Medicine have conducted a study to examine how body posture and stomach motility affect drug bioavailability. * Stomach contents, motility, and gastric fluid dynamics are also influential factors in a drug’s bioavailability. * “Our models can generate biorelevant data on drug dissolution that can provide useful and unique insights into the complex physiological processes behind the oral administration of pills,” explains the study.

Many of you’ve probably swallowed a medicine sometime in your lives. It’s very common, and many drugs are taken orally, such as tablets, capsules, syrups, or lozenges.

Even though oral medication is one of the most common types of treatment due to the fact that it’s cheap and easy to apply, it comes with a complex downside. Oral administration is actually complicated for the human body to absorb an active pharmaceutical ingredient. This is because the drug’s bioavailability (rate and extent of absorption) in the gastrointestinal tract depends on the medication’s components and the stomach’s dynamic physiological environment.

Full Story:

Researchers have conducted a study to examine how body posture and stomach motility affect the bioavailability of oral drugs.

Continue reading “Body posture affects how the stomach absorbs oral medications” | >

Circa 2021 immortality of the pancreas by inducing pluripotent cells of the pancreas.

A microwell chip facilitates the single-cell characterization of the differentiation of aggregates of human induced pluripotent stem cells into pancreatic duct-like organoids and the discovery of secreted markers of pancreatic carcinogenesis.

Read more | >

Circa 2021 Basically this article details cannabinoids that have been successfully synthesized which can lead to even greater psychiatric medicine aswell as many of other types of uses.

Abstract Cannabis has been integral to Eurasian civilization for millennia, but a century of prohibition has limited investigation. With spreading legalization, science is pivoting to study the pharmacopeia of the cannabinoids, and a thorough understanding of their biosynthesis is required to engineer strains with specific cannabinoid profiles. This review surveys the biosynthesis and biochemistry of cannabinoids. The pathways and the enzymes’ mechanisms of action are discussed as is the non-enzymatic decarboxylation of the cannabinoic acids. There are still many gaps in our knowledge about the biosynthesis of the cannabinoids, especially for the minor components, and this review highlights the tools and approaches that will be applied to generate an improved understanding and consequent access to these potentially biomedically-relevant materials. Graphical abstract.

Read more | >

A team of researchers in the Faculty of Engineering of The University of Hong Kong (HKU) has developed a coin-sized system that can read weak electrochemical signals and can be used for personalized health monitoring and the measurement of such conditions as diabetes, cardiovascular diseases and mental health. The discovery was featured on the cover of Analytical Chemistry.

The PERfECT System—an acronym for Personalized Electronic Reader for Electrochemical Transistors—is the world’s smallest system of its kind, measuring 1.5 cm x 1.5 cm x 0.2 cm and weighing only 0.4 gram. It is easily wearable, for instance integrated with a smartwatch or as a patch, to allow for continuous monitoring of biosignals such as glucose levels and antibody concentrations in blood and even sweat.

“Our wearable system is tiny, soft and imperceptible to wearers, and it can do continuous monitoring of our body condition. These features mean it has the potential to revolutionize health care technology,” said Dr. Shiming Zhang of the Department of Electrical and Electronic Engineering, who leads the HKU WISE (wearable, intelligent and ) Research Group to develop the system.

Read more | >

Gene therapy pioneer — dr. katherine high, MD — president, therapeutics, askbio.

Dr. Katherine High, MD, is President, Therapeutics, at Asklepios BioPharmaceutical (AskBio — https://www.askbio.com/), where she is also member of the AskBio Board of Directors, and has responsibility for driving the strategic direction and execution of pre-clinical and clinical programs of the company.

AskBio is a wholly owned and independently operated subsidiary of Bayer AG, set up as a fully integrated gene therapy company dedicated to developing life-saving medicines that cure genetic diseases.

Most recently, Dr. High was a Visiting Professor at Rockefeller University and previous to that, she served as President, Head of Research and Development, and a member of the Board of Directors at Spark Therapeutics (a subsidiary of Hoffmann-La Roche), where she directed the development and regulatory approval of Luxturna® (a gene therapy medication for the treatment of the ophthalmic condition Leber congenital amaurosis), and represents the first gene therapy for genetic disease to obtain regulatory approval in both the United States and Europe.

Dr. High was a longtime member of the faculty at the University of Pennsylvania and medical staff at The Children’s Hospital of Philadelphia, where she was also an Investigator of the Howard Hughes Medical Institute. She served a five-year term on the U.S. Food and Drug Administration Advisory Committee on Cell, Tissue and Gene Therapies and is a past president of the American Society of Gene & Cell Therapy.

Continue reading “Dr. Katherine High, MD — Gene Therapy Pioneer — President, Therapeutics, Asklepios BioPharmaceutical” | >